Protosera
Developer and contract-service provider focused on peptide-based biomarker discovery, mass-spectrometry peptidomics, and blood-based risk tests. Operates a registered clinical testing laboratory and provides end-to-end services from peptidome discovery (direct electrophoresis-to‑MALDI workflows) through quantitative assay verification and clinical test service delivery. Provides membrane-protein library and ligand–receptor screening methods for receptor discovery and translational target identification, and collaborates with universities and clinical partners for biomarker discovery, validation, and therapeutic target development.
Industries
Nr. of Employees
small (1-50)
Products
Blood-based peptide biomarker risk test — colorectal cancer (blood test)
A blood test that measures multiple disease-associated peptides to compute a colorectal cancer risk index using mass spectrometry-based quantitation.
Blood-based peptide biomarker risk test — pancreatic cancer (blood test)
Blood test measuring peptide markers identified from peptidome studies to assess pancreatic cancer risk.
Blood-based peptide biomarker test — liver disease risk
Blood test for assessment of current liver disease risk by measuring peptides related to cytokeratin-18 fragments and related markers.
BLOTCHIP
A proprietary mass spectrometry-based method (BLOTCHIP-MS) developed for biomarker peptide discovery and validation, targeting early diagnosis across various diseases.
BLOTCHIP-MS
A mass spectrometry-based analytical method and platform used for biomarker peptide discovery, early diagnosis, and development of companion diagnostics.
プロトキー 検査
プロトセラの独自技術BLOTCHIP-MS法を用いて血中バイオマーカーペプチドを分析し、様々な疾病リスクを確認するための検査シリーズ。
Blood-based peptide biomarker risk test — colorectal cancer (blood test)
A blood test that measures multiple disease-associated peptides to compute a colorectal cancer risk index using mass spectrometry-based quantitation.
Blood-based peptide biomarker risk test — pancreatic cancer (blood test)
Blood test measuring peptide markers identified from peptidome studies to assess pancreatic cancer risk.
Blood-based peptide biomarker test — liver disease risk
Blood test for assessment of current liver disease risk by measuring peptides related to cytokeratin-18 fragments and related markers.
BLOTCHIP
A proprietary mass spectrometry-based method (BLOTCHIP-MS) developed for biomarker peptide discovery and validation, targeting early diagnosis across various diseases.
BLOTCHIP-MS
A mass spectrometry-based analytical method and platform used for biomarker peptide discovery, early diagnosis, and development of companion diagnostics.
プロトキー 検査
プロトセラの独自技術BLOTCHIP-MS法を用いて血中バイオマーカーペプチドを分析し、様々な疾病リスクを確認するための検査シリーズ。
Services
Contract research for discovery of peptide biomarkers from serum/plasma and tissues, including high-throughput electrophoresis-to-MALDI profiling, MS/MS identification and HPLC purification.
Synthesis of isotope-labeled peptides, targeted SRM/LC-MS/MS method development, multi-marker model construction and large-scale verification studies to support clinical assay implementation.
Preparation of tissue- or cell-derived membrane protein libraries reconstituted into lipid bilayers and screening against immobilized ligands to identify receptor candidates, followed by proteomic identification.
Clinical sample testing for blood-based peptide risk assays performed in a registered hygienic testing laboratory, including sample receipt, analysis and reporting to ordering institutions.
Contract research for discovery of peptide biomarkers from serum/plasma and tissues, including high-throughput electrophoresis-to-MALDI profiling, MS/MS identification and HPLC purification.
Synthesis of isotope-labeled peptides, targeted SRM/LC-MS/MS method development, multi-marker model construction and large-scale verification studies to support clinical assay implementation.
Preparation of tissue- or cell-derived membrane protein libraries reconstituted into lipid bilayers and screening against immobilized ligands to identify receptor candidates, followed by proteomic identification.
Clinical sample testing for blood-based peptide risk assays performed in a registered hygienic testing laboratory, including sample receipt, analysis and reporting to ordering institutions.
Expertise Areas
- Peptidomics and peptidome analysis
- Mass spectrometry–based quantitative assay development and verification
- Peptide biomarker discovery and clinical translation
- Proteoliposome-based membrane protein library preparation
Key Technologies
- One-step electrophoresis-to-MALDI direct transfer
- MALDI‑TOF and tandem MALDI-MS/MS
- LC‑MS/MS for peptide sequencing
- Targeted SRM/LC‑MS/MS quantitation
News & Updates
Announcement of joint research using proteoliposome membrane-protein libraries combined with direct electrophoresis-to-MALDI and LC-MS/MS identification to comprehensively screen brain-derived membrane proteins and identify candidate receptors that bind fibrillar α-synuclein; results led to patent filing and plans for therapeutic follow-up development.
Company exhibited at Kento Fest 2025 in Osaka; exhibition report published.
Regular participation and booth exhibitions at national medical and preventive medicine conferences (examples include human dock/health-check conferences and cancer society meetings).
Joint research reporting a novel pancreatic cancer peptide marker in Journal of Gastroenterology.
Peer-reviewed publications reporting discovery and validation of peptide biomarkers for mild cognitive impairment, Alzheimer's disease and other conditions.
Partnership and business tie-up to expand nationwide availability of blood-based cancer risk tests.
Announcement of joint research using proteoliposome membrane-protein libraries combined with direct electrophoresis-to-MALDI and LC-MS/MS identification to comprehensively screen brain-derived membrane proteins and identify candidate receptors that bind fibrillar α-synuclein; results led to patent filing and plans for therapeutic follow-up development.
Company exhibited at Kento Fest 2025 in Osaka; exhibition report published.
Regular participation and booth exhibitions at national medical and preventive medicine conferences (examples include human dock/health-check conferences and cancer society meetings).
Joint research reporting a novel pancreatic cancer peptide marker in Journal of Gastroenterology.
Peer-reviewed publications reporting discovery and validation of peptide biomarkers for mild cognitive impairment, Alzheimer's disease and other conditions.
Partnership and business tie-up to expand nationwide availability of blood-based cancer risk tests.